Skip to main content
. 2014 Jan 24;4(1):94–99. doi: 10.1016/j.apsb.2013.12.013

Figure 3.

Figure 3

(A) The growth curves of B16-F10 tumors in C57BL/6 mice. (B) Digital photograph of tumors at the end of the study. (C) The weights of tumors at the end of the study. (D) The changes in the body weight of B16-F10 tumor-bearing mice. C57BL/6 mice were subcutaneously injected with B16-F10 tumor cells on day 0. Starting on day 9, mice were grouped (n=5–6) and topically treated with 5-FU cream (5%) daily for 8 consecutive days on the skin area where the tumor cells were injected. The application area was pretreated (MN+5-FU cream) or not (5-FU cream) with a microneedle roller before the application of the cream. As a positive control, mice were intravenously injected with a 5-FU solution (i.v. 5-FU) on day 9 and 15. Other controls included tumor-bearing mice left untreated, or tumor-bearing mice treated with a microneedle roller in the skin area where the tumor cells were injected (i.e., MN). The asterisks (⁎) in A indicates that the values of the 5-FU cream group and the MN+5-FU cream group are different on day 13, 15, and 17 (P<0.05). Data shown in A and C are mean±S.E.M (n=5–6). Standard deviations are not included in D for clarity (n=5–6).